Introduction
============

First described in 1935 by Pameijer, and later in 1939 by Meesmann and Wilke, Meesmann corneal dystrophy (MECD; OMIM [122100](http://www.ncbi.nlm.nih.gov/omim/?term=122100)) is a rare dominantly inherited disorder affecting the corneal epithelium \[[@r1],[@r2]\]. MECD is primarily characterized by the presence of fine round intraepithelial microcysts that are diffusely distributed or limited to the interpalpebral zone, extending to the limbus \[[@r3],[@r4]\]. Although individuals with MECD may be asymptomatic, they typically experience mild symptoms, including glare, photophobia, foreign body sensation, lacrimation, contact lens intolerance, recurrent corneal erosions, as well as deterioration in visual acuity \[[@r5]\]. The most severe cases may necessitate phototherapeutic keratectomy (PTK) and, rarely, lamellar or penetrating keratoplasty to manage corneal erosions or visual impairment secondary to subepithelial scarring and associated irregular astigmatism \[[@r6],[@r7]\]. However, symptoms are expected to recur as the abnormal limbal epithelial stem cells repopulate the corneal epithelium after PTK or keratoplasty \[[@r8],[@r9]\].

MECD was first linked to mutations in the (*KRT3*; gene ID \#3850; OMIM \#[148043](http://omim.org/entry/148043)) and keratin 12 (*KRT12*; gene ID \#3859; OMIM \#[601687](http://omim.org/entry/601687)) genes in 1997 by Irvine et al \[[@r6]\]. These genes encode the highly conserved, cornea-specific keratins K3 and K12, which are the intermediate filament proteins primarily responsible for imparting mechanical strength and structural support to corneal epithelial cells \[[@r10]\]. As corneal keratins naturally occur as obligate K3/K12 heterodimers, gene mutations altering the encoded protein of either *KRT3* or *KRT12* are expected to negatively impact the K3/K12 heterodimer complex. To date, 25 mutations in *KRT3* and *KRT12* have been identified in individuals with MECD, each located in the helix-initiation (*KRT12*) or helix-termination (*KRT3* and *KRT12*) motifs ([Table 1](#t1){ref-type="table"}). Herein, we report the first de novo mutation associated with MECD, highlighting the clinical utility of molecular genetic analysis in the diagnosis of a dominantly inherited corneal disorder in the absence of a family history. Additionally, we report a variant of unknown significance in the head domain of K3, which also represents the first potential mutation in either *KRT3* or *KRT12* associated with MECD that is not located within a helix-initiation or helix-termination motif.

###### Mutations in *KRT3* and *KRT12* associated with MECD.

  Gene      Exon                          Nucleotide change                   Amino acid change    References
  --------- ----------------------------- ----------------------------------- -------------------- -------------------
  *KRT3*    **1**                         **c.250C\>T\***                     **p.(Arg84Trp)\***   **Current study**
  7         c.1493A\>T                    p.(Glu498Val)                       \[[@r10]\]           
  7         c.1508G\>C                    p.(Arg503Pro)                       \[[@r26]\]           
  7         c.1525G\>A                    p.(Glu509Lys)                       \[[@r6]\]            
  *KRT12*   1                             c.385A\>G                           p.(Met129Val)        \[[@r27]\]
  1         c.386T\>C                     p.(Met129Thr)                       \[[@r28],[@r29]\]    
  1         c.389A\>C                     p.(Gln130Pro)                       \[[@r31],[@r32]\]    
  1         c.395T\>A                     p.(Leu132His)                       \[[@r33]\]           
  1         c.395T\>C                     p.(Leu132Pro)                       \[[@r8]\]            
  1         c.399T\>G                     p.(Asn133Lys)                       \[[@r9]\]            
  1         c.403A\>G                     p.(Arg135Gly)                       \[[@r15]\]           
  1         c.404G\>T                     p.(Arg135Ile)                       \[[@r15]\]           
  1         c.404G\>C                     p.(Arg135Thr)                       \[[@r29],[@r30]\]    
  1         c.405A\>C                     p.(Arg135Ser)                       \[[@r13]\]           
  1         c.409G\>C                     p.(Ala137Pro)                       \[[@r34]\]           
  1         c.419T\>G                     p.(Leu140Arg)                       \[[@r15]\]           
  1         c.419T\>A                     p.(Leu140Gln)                       \[[@r31]\]           
  1         c.427G\>C                     p.(Val143Leu)                       \[[@r6]\]            
  1         c.427G\>T                     p.(Val143Leu)                       \[[@r18]\]           
  6         c.1198_1199ins27              p.(Leu399_Gln400ins9)               \[[@r13]\]           
  6         c.1276A\>G                    p.(Ile426Val)                       \[[@r35]\]           
  6         c.1277T\>G                    p.(Ile426Ser)                       \[[@r28]\]           
  6         c.1285T\>G                    p.(Tyr429Asp)                       \[[@r15]\]           
  6         c.1286A\>G                    p.(Tyr429Cys)                       \[[@r26]\]           
  **6**     **c.1288_1293delinsAGCCCT**   **p.(Arg430_Arg431delinsSerPro)**   **Current study**    
  6         c.1289G\>C                    p.(Arg430Pro)                       \[[@r36]\]           
  6         c.1298T\>G                    p.(Leu433Arg)                       \[[@r37]\]           

\*Pathogenicity of this variant is uncertain.

Methods
=======

Two individuals referred to one of the authors (AJA) were recruited for this study. Proband 1 is a 60-year-old man, and proband 2 is an 8-year-old boy, both otherwise healthy at the time of enrollment. The mother and father of proband 2 were also recruited. Informed consent was obtained from all subjects according to the tenets of the Declaration of Helsinki, and the study adhered to the ARVO statement on human subjects. The Institutional Review Board at the University of California, Los Angeles approved the study described herein (UCLA IRB \#11-000020).

Slit-lamp imaging, DNA collection, and preparation
--------------------------------------------------

Saliva samples were collected from both probands and the parents of proband 2 using the Oragene Saliva Collection Kit (DNA Genotek, Inc., Ottawa, Canada). Genomic DNA was extracted from buccal epithelial cells using the Oragene prepIT•L2P protocol for genomic DNA purification (DNA Genotek, Inc.). Slit-lamp biomicroscopic imaging was performed for all individuals from whom DNA was collected.

PCR and gel extraction
----------------------

The exonic regions of *KRT3* and *KRT12* were amplified using custom designed primers (Appendix 1). Reactions were prepared as 25 μl mixtures containing 1X KAPA GC/A buffer (Kapa Biosystems, Wilmington, MA), 200 μM dNTPs, 1 unit of Kapa 2G Robust DNA polymerase (Kapa Biosystems), 240 nM of each forward and reverse primer, and 20--40 ng of genomic DNA. A C1000 Touch Thermal Cycler (Bio-Rad, Hercules, CA) was used to perform thermal cycling. Reactions were cycled with the following program: denaturation at 95 °C for 3 min; 36 cycles of annealing and extension at 95 °C for 30 s, 50--60 °C for 30 s, 72° for 30 s; and elongation at 72 °C for 10 min. Amplified DNA was purified using the QIAquick Gel Extraction Kit according to the manufacturer's instructions (Qiagen, Hilden, Germany).

DNA sequencing
--------------

Before sequencing, 15--30 ng of each amplicon was purified by treatment with 5.0 units of exonuclease I and 0.5 units of shrimp alkaline phosphatase (USB Corp., Cleveland, OH), followed by incubation at 37 °C for 15 min and inactivation at 80 °C for 15 min. Bidirectional sequencing of the purified PCR template was performed by Laragen Sequencing & Genotyping (Laragen Inc., Culver City, CA). Sequences were viewed using 4Peaks (Nucleobytes Inc., Amsterdam, The Netherlands), and the *KRT3* and *KRT12* exon and exon-intron junction sequences were compared to the NCBI reference sequences for *KRT3* (Genbank Accession: [NM_057088.2](http://www.ncbi.nlm.nih.gov/nuccore/NM_057088.2)) and KRT12 (Genbank Accession: [NM_000223](http://www.ncbi.nlm.nih.gov/nuccore/NM_000223)). Identified sequence variants were annotated according to the [HGVS](http://www.hgvs.org/mutnomen) nomenclature guidelines. The [dbSNP](http://www.ncbi.nlm.nih.gov/projects/SNP), [1000 Genomes](http://www.ncbi.nlm.nih.gov/variation/tools/1000genomes), and [Exome Aggregation Consortium](http://exac.broadinstitute.org) browser databases were used to identify the minor allele frequencies of identified variants.

Paternity testing
-----------------

DNA samples from proband 2 and his parents were submitted to Genetica DNA Laboratories, Inc. (Cincinnati, OH) for paternity testing. Genotyping was performed for a gender-associated marker, amelogenin, and 15 different short tandem repeats using the PowerPlex 16 HS System (Promega Corporation, Madison, WI).

In silico protein analysis
--------------------------

A web tool ([DNAtoprotein](http://www.dnatoprotein.com)) was used to generate an in silico translation of the mutant *KRT3* and *KRT12* sequences. [PolyPhen-2](http://genetics.bwh.harvard.edu/pph2), [SIFT](http://sift.jcvi.org/www/SIFT_chr_coords_submit.html), and [PANTHER](http://www.pantherdb.org/tools/csnpScoreForm.jsp) were used to predict the functional impact of the identified variants. [ConSurf](http://consurf.tau.ac.il) was used to predict the evolutionary conservation of the amino acids affected by each identified variant.

Results
=======

Clinical findings
-----------------

### Case 1

A 60-year-old Caucasian man (proband 1) with a history of corneal epitheliopathy since age 2 was examined by two of the authors (S.X.D. and A.J.A.). He reported experiencing episodes of foreign body sensation, tearing, stinging, photophobia, and decreased visual acuity approximately every 6 months. Corneal epithelial debridement had been performed previously, with relief of symptoms for up to 1 year. Corrected distance visual acuity (CDVA) measured 20/20 OU, and slit-lamp biomicroscopic examination revealed bilateral, diffusely distributed, fine, clear epithelial microcysts ([Figure 1A](#f1){ref-type="fig"}). Given the confluent nature of the fine epithelial microcysts, the cornea demonstrated a stippled appearance following the instillation of fluorescein dye ([Figure 1B](#f1){ref-type="fig"}). The proband's parents were deceased, he had no siblings, and his only offspring, a daughter, was not available for examination or genetic testing.

![Slit-lamp photomicrographs of two individuals with Meesmann corneal dystrophy. **A**: Proband 1, left eye. Direct illumination demonstrates subtle, fine round epithelial opacities best visualized at the pupillary border. **B**: Proband 1, left eye. Fluorescein staining reveals generalized stippling of the epithelium, produced by diffuse epithelial microcysts (inset). **C**: Proband 2, right eye. Gray-white corneal epithelial opacities are observed in the central cornea (arrowhead), and gray-white parallel epithelial lines are present in the inferior corneal periphery (arrow). **D**: Proband 2, left eye. Fluorescein staining of the peripheral, linear corneal epithelial opacities is seen.](mv-v21-1378-f1){#f1}

### Case 2

An 8-year-old Caucasian boy (proband 2) was examined by one of the authors (A.J.A.). The patient has had a history of photophobia since age 1 and was diagnosed with MECD by an outside provider following an exam under anesthesia at age 2. The proband's parents denied a family history of either MECD or corneal transplantation. Uncorrected Snellen visual acuities measured 20/200--1 OD (pinhole 20/80) and 20/80--2 OS (pinhole no improvement). Slit-lamp examination revealed diffuse, bilateral punctate gray-white epithelial opacities. In the superior and inferior corneal quadrants, the epithelial opacities appeared as parallel lines that stained with fluorescein and extended to the limbus ([Figure 1C,D](#f1){ref-type="fig"}). Both of the proband's parents were also examined and demonstrated clear corneas.

Genetic screening
-----------------

Screening of *KRT3* in proband 1 revealed three heterozygous missense variants and one synonymous substitution, but screening of *KRT12* demonstrated one heterozygous missense variant (Appendix 2). Each identified variant has been reported to be present in more than 5% of the population, except c.250C\>T (p.(Arg84Trp)) in *KRT3* exon 1, which corresponds to the head domain of the K3 protein ([Figure 2A](#f2){ref-type="fig"}). The presence of the variant was confirmed with forward and reverse sequencing, and by sequencing with a second primer pair. Although the variant was not identified in 200 control chromosomes, it has been reported to be present in 80/66,638 Europeans (0.1%) and 186/10,380 Africans (1.8%) according to the Exome Aggregation Consortium browser database, with an overall minor allele frequency (MAF) of 0.0076 per the dbSNP and 1000 Genomes databases.

![Pedigrees and chromatograms of two individuals with MECD. **A**: Pedigree of family of proband 1 and chromatogram demonstrating a portion of *KRT3* exon 1 in the proband. The chromatogram demonstrates a single heterozygous nucleotide change, c.250C\>T, in exon 1 of *KRT3*. **B**: Pedigree of family of proband 2 and chromatograms demonstrating a portion of *KRT12* exon 6 in the proband and his unaffected parents. The chromatograms reveal a heterozygous insertion/deletion variant (c.1288_1293delCGCCGCinsAGCCCT) in proband 2 (II:1) that is not present in the proband's father (I:1) or mother (I:2). Filled symbols represent affected individuals; unfilled symbols represent unaffected individuals; question marks indicate individuals of unknown affected status; symbols with a diagonal line represent deceased individuals; arrowhead designates the proband. Below each symbol in which screening of *KRT3* and *KRT12* was performed, the results are given as wild-type (+) or the identified mutation is shown.](mv-v21-1378-f2){#f2}

Screening of *KRT3* in proband 2 demonstrated two of the three missense variants and the synonymous substitution identified in proband 1, each homozygous (Appendix 2). Screening of *KRT12* demonstrated a novel heterozygous insertion/deletion variant (indel), c.1288_1293delCGCCGCinsAGCCCT (p.(Arg430_Arg431delinsSerPro)), in the helix-termination motif. The presence of this variant in exon 6 was confirmed with forward and reverse sequencing, and by sequencing with a second primer pair. The variant was not identified in the unaffected mother or father of the proband, or in 200 control chromosomes. Genotyping of the proband and his parents confirmed (with greater than 99.999% certainty) that the proband's mother and father were his biological parents ([Table 2](#t2){ref-type="table"}).

###### Determination of paternity for proband 2 by genotyping for a sex-associated marker, amelogenin (AMEL), and 15 short tandem repeats.

  Allelic Marker   Father (CDDL267)   Child (CDDL266)   Mother (CDDL268)   Random Match Probability \[[@r38]\]             
  ---------------- ------------------ ----------------- ------------------ ------------------------------------- ---- ---- -------
  AMEL             X                  Y                 Y                  X                                     X    X    N/A
  CSF1PO           10                 13                13                 12                                    12   12   0.112
  D13S317          11                 12                12                 9                                     9    13   0.085
  D16S539          11                 12                12                 12                                    12   12   0.089
  D18S51           12                 18                18                 12                                    12   12   0.028
  D21S11           30                 32.2              32.2               29                                    29   29   0.039
  D3S1358          18                 17                17                 16                                    16   14   0.075
  D5S818           13                 12                12                 11                                    11   10   0.158
  D7S820           8                  9                 9                  8                                     8    12   0.065
  D8S1179          13                 10                10                 10                                    10   12   0.067
  FGA              20                 22                22                 20                                    20   22   0.036
  PENTA D          10                 13                13                 12                                    12   9    0.004
  PENTA E          12                 7                 7                  13                                    13   12   0.176
  TH01             7                  9.3               9.3                9                                     9    7    0.081
  TPOX             11                 9                 9                  11                                    11   11   0.195
  VWA              18                 18                18                 17                                    17   15   0.062

Note: There is a greater than 99.999% percent probability that both parents are the biologic parents.

Protein in silico analysis
--------------------------

In silico analysis with PolyPhen-2 and PANTHER predicted p.(Arg84Trp) in K3 to be likely damaging to protein function; however, SIFT analysis predicted that the missense change would be tolerated ([Table 3](#t3){ref-type="table"}). In addition, ConSurf assigned amino acid 84 of K3 a score of 4 (scale: 1--9), indicative of slightly variable conservation across species.

###### Summary of in silico analysis results.

  Gene      Nucleotide change               Amino acid change               Polyphen-2          SIFT                PANTHER             ConSurf (score\*)
  --------- ------------------------------- ------------------------------- ------------------- ------------------- ------------------- -----------------------
  *KRT3*    c.250C\>T                       p.(Arg84Trp)                    Probably damaging   Tolerated           Probably damaging   Slightly variable (4)
  *KRT12*   c.1288_1293delCGCCGCinsAGCCCT   p.(Arg430_Arg431delinsSerPro)   Probably damaging   Probably damaging   Probably damaging   High (9)

\* Scale: 1 to 9.

Both missense mutations identified in *KRT12* in proband 2, p.(Arg430Ser) and p.(Arg431Pro), were predicted to be damaging to the function of the encoded protein by all three protein prediction tools. ConSurf calculations assigned amino acid 430 a score of 9, which indicates the highest level of conservation across species, and amino acid 431 a score of 5, which indicates average conservation across species.

Discussion
==========

Keratins are a group of structural proteins in the epithelia of the skin, hair, nails, and cornea. These proteins occur as obligate heteropolymers, assembled from dimers composed of type I and type II intermediate filaments. In the cornea, the type I intermediate filament is K12, but the type II intermediate filament is K3 \[[@r11]\]. Structurally, intermediate filaments consist of an N-terminal head domain, a central α-helical rod domain that begins with a helix-initiation motif and ends with a helix-termination motif, and a C-terminal tail domain ([Figure 3](#f3){ref-type="fig"}) \[[@r12],[@r13]\]. The rod domain, and in particular the helix boundary motifs, is highly conserved across species. Thus, mutations in this region often substantially alter the structure of the encoded keratin protein and negatively impact keratin function \[[@r14],[@r15]\]. Specifically, mutations in the helix boundary motifs have been observed to compromise intermediate filament assembly during the early stages of filament elongation, resulting in cytoplasmic filament clumping and more severe disease phenotypes than those associated with mutations of other keratin protein domains \[[@r11],[@r14],[@r16]\]. Keratin gene mutations have consequently been linked to several tissue-specific fragility syndromes, with certain features commonly observed, such as cytolysis, hyperkeratosis, and filament aggregation \[[@r16]\].

![Protein structure of K3 and K12, constructed using data from the [Human Intermediate Filament Database](http://www.interfil.org). Each intermediate filament consists of an N-terminal head domain, a central α-helical rod domain, and a C-terminal tail domain. The rod domain is composed of four helical segments (1A (helix-initiation motif), 1B, 2A, and 2B (helix-termination motif)), which are connected to each other by non-helical linker regions (L1, L12, L2). Variants reported in current (\*) and previous studies are depicted in their respective amino acid locations.](mv-v21-1378-f3){#f3}

The head domain, while fairly conserved, varies the most between tissue-specific keratins, and therefore accounts for the diversity of keratins among epithelia \[[@r16]\]. In contrast to the helical rod domains, which form the backbone of the keratin filaments and are responsible for maintaining the structural integrity of the heterodimer unit, the head domain plays a more significant role in higher-order intermediate filament assembly \[[@r12],[@r16]\]. These assembly functions include intermediate filament organization, dimer binding to form heterotetramers, and end-to-end linkage of the polymers to form keratin filaments \[[@r12],[@r17]\]. Though not yet well understood, the ability of the head domain to confer tissue-specific properties to keratins is attributed to post-translational modification of this region, which possesses numerous sites that serve as substrates for phosphorylation \[[@r11],[@r17]\].

Before this report, no keratin mutations in the head domain of either K3 or K12 had been identified that are presumed to cause MECD, although head domain mutations in other keratin proteins have been implicated in various dermatologic disorders, including epidermolysis bullosa simplex \[[@r11]\]. Nielsen et al. previously reported two single nucleotide polymorphisms (SNVs), c.43C\>T (p.(Pro15Ser)) and c.55C\>T (p.(Arg19Trp)), in the head domain of K12 in a family with ocular findings of MECD \[[@r18]\]. However, neither of the SNVs is likely pathogenic, as the MAF for each of these variants is 0.3095 and 0.0537, respectively, and the affected family members harbored a presumed pathogenic novel heterozygous mutation in the helix-initiation motif of K12. The K3 mutation we report in proband 1 is the sole coding region variant identified in *KRT3* and *KRT12* with an MAF of less than 0.05, although the associated MAF of 0.0076 is likely greater than the population prevalence of MECD. Additionally, although PolyPhen-2 and PANTHER predicted the variant to be damaging to protein function, SIFT analysis predicted tolerance of the variant. Despite the questions regarding the variant's pathogenicity, it remains possible that the variant is associated with MECD, given the well-established association between keratin mutations and MECD. Unfortunately, as the parents of the proband were unavailable for examination, we were unable to establish an association between p.(Arg84Trp) in *KRT3* and MECD in other members of this family, and thus present it as a variant of uncertain significance.

Previous studies by Liao et al. and Allen et al. provided a proposed mechanism for how identified *KRT3* and *KRT12* mutations lead to the development of the corneal epithelial abnormalities that characterize Meesmann corneal dystrophy \[[@r19],[@r20]\]. These investigators demonstrated a disruption of the normal intracellular keratin filament formation in cultured corneal epithelial cells transfected with mutant cDNA constructs, as well as rescue of normal keratin filament formation with allele-specific siRNA inhibition of the mutant allele \[[@r19],[@r20]\]. Although it is likely that each of the identified mutations in *KRT3* and *KRT12*, including those that we report, also causes a disruption of the intracellular keratin filament network, similar functional studies must be performed to provide additional evidence for, or alternatively, to provide evidence against, the pathogenicity of each variant.

To date, all 25 mutations in *KRT3* and *KRT12* identified in individuals with MECD have been located in the helix boundary motifs of the respective keratin proteins ([Figure 3](#f3){ref-type="fig"}). The majority (15/25) of the mutations are in the helix-initiation motif of K12; the remainder are in the helix-termination motifs of K3 and K12. We present a novel mutation, and the first reported indel, in *KRT12* associated with a previously unreported phenotype of MECD, which we demonstrate to have arisen spontaneously. De novo mutations have been identified in three other genes associated with corneal dystrophies: *TGFBI* (gene ID \#21810; OMIM \#[601692](http://omim.org/entry/601692)); *ZEB1* (gene ID \#21417; OMIM \#[189909](http://omim.org/entry/189909)), associated with posterior polymorphous corneal dystrophy 3; and *UBIAD1* (gene ID \#29914; OMIM \#[611632](http://omim.org/entry/611632); associated with Schnyder corneal dystrophy) \[[@r21]-[@r25]\]. Such cases of de novo dominantly inherited corneal dystrophies highlight the utility of molecular genetic analysis to confirm the diagnosis of a suspected corneal dystrophy that is questioned given the absence of a family history. We also report a missense mutation of unknown significance in *KRT3*, only the fourth to be associated with MECD and the first in the head domain of K3. Although this variant has not been demonstrated to be pathogenic, the possibility that disease-causing variants associated with MECD may not be restricted to primary sequence alterations of either the helix-initiation or helix-termination motifs of K3 and K12 should be considered.
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Note: letters indicate primer pairs amplifying different regions of an exon, whereas numbers indicate alternative primer pairs used to sequence the entirety of an exon. To access the data, click or select the words "[Appendix 1](http://www.molvis.org/molvis/v21/appendices/mv-v21-1378-app-1.docx)."

\*Homozygous change. To access the data, click or select the words "[Appendix 2](http://www.molvis.org/molvis/v21/appendices/mv-v21-1378-app-2.docx)."
